Skip to main content
UniHealth

Doctor search

James D Palmer, MD

Ophthalmology · Mountain View

NPI 1053306381

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
33
9 carriers
Offices
4

Offices

4 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group

Looking this up.

Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.

Plans that list them

33 plans · 9 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Palmer’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

33 of 33 plans

Plans whose provider directory lists this clinician
Alignment Health Advantage PPO (PPO)Alignment Health PlanListedOct 3, 2026
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
Anthem Medicare Advantage (HMO-POS)Anthem Blue CrossListedOct 3, 2026
Anthem Prime (HMO-POS)Anthem Blue Cross Partnership PlanListedOct 3, 2026
Astiva Health C-SNP WOW - NorCal (HMO C-SNP)Astiva HealthListedSep 27, 2026
Astiva Health Premier Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Astiva Health Savings Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Central Health Classic Care Plan III (HMO)Central Health Medicare PlanListedAug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)Central Health Medicare PlanListed, may be out of dateSep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Valor Care Plan (HMO)Central Health Medicare PlanListedAug 15, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G26383 · Current

Licensed to practise in California · since 1974 · expires 2027-01-31 · Tulane University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Peninsula Medical Center
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.139BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.242BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.21 (0.27 to 2.15) · 1,258 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.81 (0.51 to 1.1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths155.44 (112.67 to 198.21) · 90 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.5 · 32 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 82 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 188 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9 · 473 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.8 · 342 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 485 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 3,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.4) · 6,904 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,052 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.41 (1.43 to 5.39) · 1,695 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.72 (0.17 to 3.28) · 665 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.66 to 3.56) · 1,545 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.1 (1.3 to 12.9) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.96 (2.63 to 9.29) · 653 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.15 to 3.08) · 418 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.78) · 5,539 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 192 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.215No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.263No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.74No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.3 · 300 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19 · 702 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits1.2 · 207 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13.6 · 531 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits24.3 · 343 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.1 · 449 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.5 (2.8 to 7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.6 (6.7 to 13.7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 189 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11 · 45 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 117 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (9.7 to 17.2) · 584 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.2) · 764 casesNo differentJan 2024 – Dec 2024

What patients said (523 patients answered, 27% of those asked)

Patient survey stars by topic at Peninsula Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Peninsula Medical Center
Room was "always" clean76%
Nurses "always" communicated well81%
Doctors "always" communicated well80%
Staff "always" explained58%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$3,234,949

Medicare paid this office $3,234,949 for 1,013 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection, faricimab-svoa, 0.1 mg151$1,331,544None
Injection, aflibercept, 1 mg216$896,745None
Injection, aflibercept hd, 1 mg71$383,857None
Injection of drug into eye366$168,840$112
Imaging of retina904$93,032$39
See all 15 services
Every Original Medicare service billed
Injection, faricimab-svoa, 0.1 mg151$1,331,544None
Injection, aflibercept, 1 mg216$896,745None
Injection, aflibercept hd, 1 mg71$383,857None
Injection of drug into eye366$168,840$112
Imaging of retina904$93,032$39
Return visit (30+ min)353$79,464$121
Established patient complete exam of visual system523$56,914$107
Exam of retinal blood vessels using a special camera after injection of a dye188$37,399$163
Short return visit (20+ min)318$32,307$74
Established patient problem focused exam of visual system226$21,306$80
New patient visit (45+ min)80$11,512$144
New patient complete exam of visual system85$11,221$132
Photography of the retina119$4,994$34
2d ultrasound scan of eye tissue and structures25$1,597$47
Extended exam of the back part of the eye with retinal drawing17$348$20

Procedures Medicare counted

Procedure volume Medicare published
Cataract surgery1-10None

Who their Medicare patients are

1,013 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 25% · Women 56% · Also on Medicaid 31% · Health risk score 1.44. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 75% · Diabetes 40% · Chronic kidney disease 28% · Coronary heart disease 23% · Heart failure 16% · Atrial fibrillation 16% · Cancer 14% · Depression 11% · COPD 10% · Dementia 7% · Stroke 7%.

The office billed $9,616,471, Medicare allowed $4,123,832 and paid $3,234,949; for 59,119 services of 51 kinds; $2,661,895 of it was for drugs given in the office and $573,054 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241,01359,119781.44$9,616,471$3,234,949
202398134,678781.38$8,829,540$3,065,211
202289413,829781.38$8,585,745$3,061,058
20211,01214,003781.36$9,388,609$3,523,726
202090913,803781.46$8,852,868$3,298,751
20191,04215,238781.45$8,441,926$3,227,313
20181,02012,618771.40$6,575,674$2,582,029
201798111,589771.53$5,269,641$2,157,988
201695311,658781.54$3,832,633$1,977,921
201594611,228781.49$3,394,830$1,793,929
201497213,015781.44$3,086,184$1,765,522
201396814,544781.43$3,369,805$2,038,562

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 16 services

Original Medicare services billed in 2023
Injection, aflibercept, 1 mg295$1,698,393None
Injection, faricimab-svoa, 0.1 mg120$702,897None
Injection of drug into eye378$167,637$106
Imaging of retina875$89,752$37
Injection, ranibizumab, 0.1 mg25$73,498None
Return visit (30+ min)327$57,579$103
Established patient complete exam of visual system497$52,943$104
Short return visit (20+ min)383$47,576$79
Exam of retinal blood vessels using a special camera after injection of a dye183$27,328$127
Established patient problem focused exam of visual system209$16,925$69
New patient complete exam of visual system118$15,574$132
New patient visit (45+ min)74$10,535$142
Photography of the retina109$4,593$32
Compounded drug, not otherwise classified13$1,603None
2d ultrasound scan of eye tissue and structures19$1,025$43
Extended exam of the back part of the eye with retinal drawing31$559$17

2022: 16 services

Original Medicare services billed in 2022
Injection, aflibercept, 1 mg307$2,118,312None
Injection, ranibizumab, 0.1 mg61$346,325None
Injection of drug into eye359$175,258$105
Imaging of retina814$89,514$37
Injection, faricimab-svoa, 0.1 mg23$71,620None
Established patient problem focused exam of visual system461$56,508$79
Established patient complete exam of visual system529$54,852$101
Return visit (30+ min)229$30,355$99
Exam of retinal blood vessels using a special camera after injection of a dye186$25,489$119
Short return visit (20+ min)157$16,342$84
New patient visit (45+ min)114$14,672$129
New patient complete exam of visual system29$3,962$137
Photography of the retina88$3,828$33
Compounded drug, not otherwise classified12$2,078None
Extended exam of the back part of the eye with retinal drawing48$1,087$22
2d ultrasound scan of eye tissue and structures16$941$43

2021: 15 services

Original Medicare services billed in 2021
Injection, aflibercept, 1 mg315$2,362,932None
Injection, ranibizumab, 0.1 mg74$528,190None
Injection of drug into eye397$203,296$108
Established patient problem focused exam of visual system616$119,146$84
Imaging of retina852$98,217$38
Established patient complete exam of visual system534$47,723$85
Exam of retinal blood vessels using a special camera after injection of a dye199$26,906$117
New patient visit (45+ min)184$25,749$140
Return visit (30+ min)155$19,205$122
Photography of the retina227$9,229$35
Compounded drug, not otherwise classified21$4,437None
Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye11$3,188$245
Short return visit (20+ min)30$2,933$84
Extended exam of the back part of the eye with retinal drawing99$2,581$23
2d ultrasound scan of eye tissue and structures27$1,434$42

2020: 13 services

Original Medicare services billed in 2020
Injection, aflibercept, 1 mg271$2,031,722None
Injection, ranibizumab, 0.1 mg84$656,980None
Injection of drug into eye370$174,083$96
Established patient complete exam of visual system741$132,317$100
Imaging of retina732$87,722$37
Established patient problem focused exam of visual system354$86,976$81
Exam of retinal blood vessels using a special camera after injection of a dye188$23,291$100
New patient visit (45+ min)170$22,187$131
Photography of the retina258$13,065$40
Compounded drug, not otherwise classified32$9,006None
Extended exam of the back part of the eye with retinal drawing89$2,602$23
2d ultrasound scan of eye tissue and structures27$1,711$48
Short return visit (20+ min)14$1,125$70

2019: 13 services

Original Medicare services billed in 2019
Injection, aflibercept, 1 mg244$1,765,941None
Injection, ranibizumab, 0.1 mg114$774,400None
Injection of drug into eye379$170,591$95
Established patient complete exam of visual system862$160,174$102
Imaging of retina841$91,837$38
Established patient problem focused exam of visual system397$84,367$80
Exam of retinal blood vessels using a special camera after injection of a dye288$33,233$90
New patient visit (45+ min)209$25,504$122
Photography of the retina368$20,978$44
Compounded drug, not otherwise classified63$11,608None
Examination of eye by ophthalmoscope with retinal drawing82$4,095$23
Examination of eye by ophthalmoscope with retinal drawing62$2,580$26
2d ultrasound scan of eye tissue and structures25$1,800$56

2018: 20 services

Original Medicare services billed in 2018
Injection, aflibercept, 1 mg188$1,392,122None
Injection, ranibizumab, 0.1 mg80$536,764None
Established patient complete exam of visual system826$163,880$102
Injection of drug into eye333$138,537$94
Imaging of retina833$89,281$38
Established patient problem focused exam of visual system354$66,508$77
New patient visit (45+ min)214$27,008$126
Exam of retinal blood vessels using a special camera after injection of a dye210$20,588$80
Compounded drug, not otherwise classified95$17,385None
Photography of the retina274$16,517$49
Repair of detached retina with drainage and removal of eye fluid between lens and retina11$12,229$1,112
Destruction of growth of retina using a laser12$5,805$484
Destruction of leaking blood vessels of retina using laser14$4,873$287
Injection, triamcinolone acetonide, preservative free, 1 mg11$2,666None
Examination of eye by ophthalmoscope with retinal drawing53$2,412$21
Examination of eye by ophthalmoscope with retinal drawing51$2,188$25
2d ultrasound scan of eye tissue and structures18$1,662$64
Return visit (30+ min)18$1,119$59
Short return visit (20+ min)11$641$53
Short return visit11$267$24

2017: 17 services

Original Medicare services billed in 2017
Injection, aflibercept, 1 mg174$1,210,462None
Injection, ranibizumab, 0.1 mg49$357,198None
Established patient complete exam of visual system814$148,915$100
Injection of drug into eye315$122,389$91
Imaging of retina835$91,693$37
Established patient problem focused exam of visual system381$73,522$74
New patient visit (45+ min)223$27,218$122
Compounded drug, not otherwise classified117$21,639None
Photography of the retina207$16,245$62
Exam of retinal blood vessels using a special camera after injection of a dye158$14,015$72
Destruction of growth of retina using a laser15$8,694$483
Destruction of leaking blood vessels of retina using laser15$5,668$298
Return visit (30+ min)28$2,593$89
2d ultrasound scan of eye tissue and structures19$2,312$83
Examination of eye by ophthalmoscope with retinal drawing52$1,914$20
Examination of eye by ophthalmoscope with retinal drawing38$1,614$25
Short return visit (20+ min)17$1,130$59

2016: 17 services

Original Medicare services billed in 2016
Injection, aflibercept, 1 mg167$1,038,163None
Injection, ranibizumab, 0.1 mg42$326,412None
Established patient complete exam of visual system742$140,535$101
Injection of drug into eye303$109,590$92
Imaging of retina799$101,934$41
Established patient problem focused exam of visual system374$79,532$75
New patient visit (45+ min)243$30,580$126
Exam of retinal blood vessels using a special camera after injection of a dye139$28,494$99
Compounded drug, not otherwise classified120$18,390None
Photography of the retina178$14,199$68
Destruction of growth of retina using a laser20$10,027$456
Destruction of leaking blood vessels of retina using laser13$5,010$278
Injection, triamcinolone acetonide, preservative free, 1 mg18$3,625None
2d ultrasound scan of eye tissue and structures25$3,495$87
Examination of eye by ophthalmoscope with retinal drawing54$2,172$24
Examination of eye by ophthalmoscope with retinal drawing46$1,854$21
Short return visit (20+ min)12$867$62

2015: 18 services

Original Medicare services billed in 2015
Injection, aflibercept, 1 mg155$887,024None
Injection, ranibizumab, 0.1 mg48$315,317None
Established patient complete exam of visual system750$140,865$99
Injection of drug into eye290$104,727$94
Imaging of retina790$101,439$41
Established patient problem focused exam of visual system330$56,443$75
Exam of retinal blood vessels using a special camera after injection of a dye133$29,628$100
New patient visit (45+ min)221$29,018$131
Destruction of leaking blood vessels of retina using laser16$17,469$919
Destruction of growth of retina using a laser27$14,428$465
Unclassified biologics102$12,843None
Photography of the retina156$12,613$67
Injection, triamcinolone acetonide, preservative free, 1 mg23$5,540None
Compounded Drug, Not Otherwise Classified47$3,984$55
2d ultrasound scan of eye tissue and structures20$2,363$88
Short return visit (20+ min)20$1,831$63
Examination of eye by ophthalmoscope with retinal drawing32$1,373$24
Examination of eye by ophthalmoscope with retinal drawing28$1,018$23

2014: 18 services

Original Medicare services billed in 2014
Injection, aflibercept, 1 mg136$747,396None
Injection, ranibizumab, 0.1 mg74$406,277None
Established patient complete exam of visual system749$145,977$99
Injection of drug into eye313$107,085$90
Imaging of retina789$104,626$41
Established patient problem focused exam of visual system334$46,720$75
Exam of retinal blood vessels using a special camera after injection of a dye171$35,183$100
New patient visit (45+ min)247$33,076$134
Destruction of leaking blood vessels of retina using laser21$26,121$933
Destruction of growth of retina using a laser34$20,523$477
Unclassified biologics136$17,884None
Photography of the retina186$13,582$66
Injection, triamcinolone acetonide, preservative free, 1 mg43$9,799None
2d ultrasound scan of eye tissue and structures24$2,354$87
Examination of eye by ophthalmoscope with retinal drawing60$2,049$23
Short return visit (20+ min)20$960$44
Examination of eye by ophthalmoscope with retinal drawing24$830$25
Imaging of optic nerve11$517$40

2013: 18 services

Original Medicare services billed in 2013
Injection, aflibercept, 1 mg111$738,833None
Injection, ranibizumab, 0.1 mg122$619,216None
Established patient complete exam of visual system752$148,589$100
Injection of drug into eye339$123,403$88
Imaging of retina770$104,490$41
Exam of retinal blood vessels using a special camera after injection of a dye228$52,846$104
Established patient problem focused exam of visual system303$37,605$74
Destruction of growth of retina using a laser55$36,423$486
Destruction of leaking blood vessels of retina using laser27$31,935$939
New patient visit (45+ min)241$31,456$131
Photography of the retina235$20,099$67
Unclassified biologics137$18,937None
Removal of membrane of retina11$13,743$1,249
Injection, triamcinolone acetonide, preservative free, 1 mg40$9,887None
2d ultrasound scan of eye tissue and structures40$4,232$90
Short return visit (20+ min)29$1,898$63
Examination of eye by ophthalmoscope with retinal drawing51$1,281$23
Examination of eye by ophthalmoscope with retinal drawing41$1,041$25

Medicaid work

$281,134 in 2024

Medicaid paid $281,134 for 2,697 billed services this clinician did in 2024, up to 102 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Aflibercept injection323$143,846
Intravitreal injection of a pharmacologic agent (separate procedure)682$63,520
Injection, faricimab-svoa, 0.1 mg155$52,593
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina1,008$12,544
Return visit (30+ min)232$3,436
Short return visit (20+ min)129$2,133
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST124$1,613
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI44$1,450
Medicaid work by year
20242,6978102$281,134
20233,7141199$418,282
20223,57110109$481,864
20213,4499104$312,374
20203,107788$278,629
20192,871878$187,190
20182,292979$114,980
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Aflibercept injection655$275,843
Intravitreal injection of a pharmacologic agent (separate procedure)919$101,982
Injection, faricimab-svoa, 0.1 mg56$18,260
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina1,241$14,963
Return visit (30+ min)301$2,331
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI94$1,663
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST159$1,121
Short return visit (20+ min)224$831
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient36$704
Injection, bevacizumab, 10 mg17$480
New patient visit (45+ min)12$104

2022

Largest Medicaid services in 2022
Aflibercept injection775$397,442
Intravitreal injection of a pharmacologic agent (separate procedure)817$64,845
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina1,106$10,160
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient277$2,223
Injection, bevacizumab, 10 mg64$2,106
Return visit (30+ min)177$1,461
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI99$1,442
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST179$1,373
New patient visit (45+ min)12$473
Short return visit (20+ min)65$340

2021

Largest Medicaid services in 2021
Aflibercept injection680$246,728
Intravitreal injection of a pharmacologic agent (separate procedure)793$51,596
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina989$5,454
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient542$3,605
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST190$1,793
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI63$1,215
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT68$701
Return visit (30+ min)81$687
New patient visit (45+ min)43$595

2020

Largest Medicaid services in 2020
Aflibercept injection541$222,778
Intravitreal injection of a pharmacologic agent (separate procedure)698$42,951
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina823$4,522
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST475$4,335
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient385$2,891
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI74$581
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT111$570

2019

Largest Medicaid services in 2019
Aflibercept injection338$128,128
Intravitreal injection of a pharmacologic agent (separate procedure)582$45,446
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST482$4,235
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina728$3,051
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI184$1,858
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient325$1,826
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT190$1,336
New patient visit (45+ min)42$1,311

2018

Largest Medicaid services in 2018
Aflibercept injection231$71,599
Intravitreal injection of a pharmacologic agent (separate procedure)463$34,435
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina758$3,087
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST460$2,905
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient238$1,508
FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI57$646
New patient visit (45+ min)26$450
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT47$269
Compounded drug, not otherwise classified12$81

Drugs they prescribed that Part D paid

$50,254

Pharmacies billed $50,254 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 552) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

425 generic and 127 brand-name prescriptions · $50,254 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Bromfenac77$11,199$145
Xiidra11$7,379$671
Brimonidine39$3,632$93
Prednisolone Acetate42$1,479$35
Diclofenac143$1,393$10
See all 11 drugs
Every Part D drug this clinician prescribed
Bromfenac77$11,199$145
Xiidra11$7,379$671
Brimonidine39$3,632$93
Prednisolone Acetate42$1,479$35
Diclofenac143$1,393$10
Neomycin-Polymyxin-Dexameth86$845$10
Ketorolac Tromethamine19$493$26
Latanoprost46$455$10
Timolol Maleate20$424$21
Dorzolamide11$156$14
Dorzolamide-Timolol12$124$10

Year by year

Part D prescribing by year
20245521340% (0)23%$50,254
20234991300% (0)None$52,605
20224741170% (0)None$53,881
20214071030% (0)55%$55,864
202043695None64%$65,703
2019530120None65%$72,187
2018495111None63%$60,859
2017516102None61%$65,522
2016422105None63%$53,193
2015380105None55%$45,668
20143401020% (0)59%$41,039
2013447141None55%$43,487

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 13 drugs

Part D drugs prescribed in 2023
Restasis13$15,865$1,220
Bromfenac22$4,382$199
Alphagan P13$3,300$254
Brimonidine43$2,818$66
Brimonidine Tartrate-Timolol14$2,609$186
Prednisolone Acetate59$1,953$33
Diclofenac118$1,444$12
Neomycin-Polymyxin-Dexameth62$937$15
Atropine Sulfate19$665$35
Latanoprost31$644$21
Ketorolac Tromethamine19$587$31
Timolol Maleate26$476$18
Dorzolamide11$340$31

2022: 11 drugs

Part D drugs prescribed in 2022
Prolensa19$6,818$359
Brimonidine40$3,552$89
Bromfenac13$2,145$165
Prednisolone Acetate55$1,756$32
Ketorolac Tromethamine31$1,601$52
Diclofenac88$1,176$13
Atropine Sulfate21$846$40
Neomycin-Polymyxin-Dexameth38$567$15
Latanoprost36$524$15
Dorzolamide11$413$38
Timolol Maleate27$380$14

2021: 10 drugs

Part D drugs prescribed in 2021
Combigan16$4,677$292
Prolensa12$3,800$317
Brimonidine35$2,417$69
Prednisolone Acetate50$2,361$47
Ketorolac Tromethamine29$1,403$48
Diclofenac84$1,080$13
Latanoprost30$768$26
Atropine Sulfate16$750$47
Neomycin-Polymyxin-Dexameth33$494$15
Timolol Maleate15$251$17

2020: 12 drugs

Part D drugs prescribed in 2020
Ilevro28$9,448$337
Prolensa27$8,663$321
Alphagan P18$5,100$283
Simbrinza23$4,063$177
Brimonidine26$3,648$140
Combigan14$2,953$211
Prednisolone Acetate57$2,854$50
Ketorolac Tromethamine41$2,260$55
Diclofenac64$937$15
Latanoprost29$934$32
Timolol Maleate22$577$26
Neomycin-Polymyxin-Dexameth29$501$17

2019: 16 drugs

Part D drugs prescribed in 2019
Ilevro42$12,098$288
Nevanac11$8,416$765
Prolensa26$7,202$277
Restasis12$7,156$596
Alphagan P28$5,605$200
Simbrinza33$5,593$169
Durezol22$4,598$209
Azopt12$4,358$363
Brimonidine23$2,734$119
Prednisolone Acetate58$2,624$45
Timolol Maleate22$2,151$98
Combigan12$2,149$179
Ketorolac Tromethamine43$1,734$40
Latanoprost53$1,101$21
Neomycin-Polymyxin-Dexameth52$778$15
Diclofenac50$702$14

2018: 14 drugs

Part D drugs prescribed in 2018
Ilevro46$12,253$266
Restasis17$10,931$643
Prolensa14$4,184$299
Simbrinza20$3,449$172
Durezol17$3,301$194
Alphagan P15$2,606$174
Prednisolone Acetate61$2,571$42
Brimonidine28$2,110$75
Combigan11$2,077$189
Ketorolac Tromethamine39$1,597$41
Timolol Maleate26$1,484$57
Latanoprost65$1,400$22
Neomycin-Polymyxin-Dexameth55$864$16
Diclofenac34$439$13

2017: 16 drugs

Part D drugs prescribed in 2017
Restasis22$12,345$561
Nevanac30$12,094$403
Alphagan P41$7,182$175
Durezol21$4,355$207
Simbrinza17$3,249$191
Brimonidine24$3,115$130
Ilevro12$2,929$244
Travatan Z16$2,891$181
Timolol Maleate28$2,656$95
Prednisolone Acetate47$2,009$43
Combigan12$1,779$148
Latanoprost74$1,145$15
Diclofenac55$804$15
Ketorolac Tromethamine17$591$35
Neomycin-Polymyxin-Dexameth40$570$14
Dorzolamide-Timolol11$226$21

2016: 13 drugs

Part D drugs prescribed in 2016
Nevanac34$12,780$376
Restasis17$8,085$476
Alphagan P32$5,764$180
Brimonidine21$3,242$154
Simbrinza21$2,763$132
Durezol11$2,288$208
Travatan Z11$1,838$167
Prednisolone Acetate29$1,788$62
Timolol Maleate24$1,751$73
Neomycin-Polymyxin-Dexameth44$803$18
Diclofenac36$693$19
Latanoprost57$639$11
Ketorolac Tromethamine11$252$23

2015: 11 drugs

Part D drugs prescribed in 2015
Nevanac29$13,265$457
Restasis18$10,346$575
Timolol Maleate28$2,594$93
Durezol14$2,383$170
Alphagan P15$2,103$140
Brimonidine22$1,775$81
Lumigan11$1,493$136
Neomycin-Polymyxin-Dexameth73$1,201$16
Prednisolone Acetate21$897$43
Latanoprost45$463$10
Diclofenac27$336$12

2014: 12 drugs

Part D drugs prescribed in 2014
Restasis27$9,363$347
Bromfenac27$9,279$344
Travatan Z16$3,337$209
Nevanac11$3,180$289
Azopt14$2,182$156
Alphagan P19$1,959$103
Combigan13$1,369$105
Timolol Maleate15$1,072$71
Latanoprost61$881$14
Neomycin-Polymyxin-Dexameth36$640$18
Prednisolone Acetate11$267$24
Diclofenac19$247$13

2013: 14 drugs

Part D drugs prescribed in 2013
Restasis23$8,120$353
Nevanac25$6,527$261
Bromday17$4,431$261
Combigan31$3,094$100
Bromfenac17$3,087$182
Travatan Z16$2,931$183
Alphagan P26$2,580$99
Azopt18$2,344$130
Durezol15$1,878$125
Neomycin-Polymyxin-Dexameth56$976$17
Latanoprost46$948$21
Diclofenac35$799$23
Prednisolone Acetate27$695$26
Timolol Maleate31$574$19

Money from drug and device companies

$271 in 2025

Industry payments by year
202569None$271
2024710None$394
2023922None$1,010
2022510None$367
202158None$395
202022None$40
2019710None$1,091

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Genentech USAVabysmo$69
2 payments
  • Meals for Vabysmo · 2025-12-12 · $35
  • Meals for Vabysmo · 2025-04-16 · $34
Regeneron Healthcare SolutionsEylea Hd$67
2 payments
  • Meals for Eylea Hd · 2025-10-01 · $37
  • Meals for Eylea Hd · 2025-05-28 · $30
Regeneron PharmaceuticalsEylea Hd$47
2 payments
  • Meals for Eylea Hd · 2025-10-31 · $20
  • Meals for Eylea Hd · 2025-05-09 · $26
ANI PharmaceuticalsPurified Cortrophin Gel$33
1 payment
  • Meals for Purified Cortrophin Gel · 2025-02-25 · $33
Harrow EyeTriesence$30
1 payment
  • Meals for Triesence · 2025-09-17 · $30
Astellas Pharma USIzervay$25
1 payment
  • Meals for Izervay · 2025-11-24 · $25
See all 9 published payments
Every published payment
Genentech USAMeals · 2025-12-12Vabysmo$35
Astellas Pharma USMeals · 2025-11-24Izervay$25
Regeneron PharmaceuticalsMeals · 2025-10-31Eylea Hd$20
Regeneron Healthcare SolutionsMeals · 2025-10-01Eylea Hd$37
Harrow EyeMeals · 2025-09-17Triesence$30
Regeneron Healthcare SolutionsMeals · 2025-05-28Eylea Hd$30
Regeneron PharmaceuticalsMeals · 2025-05-09Eylea Hd$26
Genentech USAMeals · 2025-04-16Vabysmo$34
ANI PharmaceuticalsMeals · 2025-02-25Purified Cortrophin Gel$33
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $394

Payments by company in 2024
RxSightRxsight Contact Lens$114
1 payment
  • Meals for Rxsight Contact Lens · 2024-06-12 · $114
Genentech USAVabysmo$100
3 payments
  • Meals for Vabysmo · 2024-09-18 · $35
  • Meals for Vabysmo · 2024-05-22 · $35
  • Meals for Vabysmo · 2024-03-15 · $30
Regeneron Healthcare SolutionsEylea Hd$71
2 payments
  • Meals for Eylea Hd · 2024-12-18 · $34
  • Meals for Eylea Hd · 2024-04-18 · $37
ANI PharmaceuticalsPurified Cortrophin Gel$33
1 payment
  • Meals for Purified Cortrophin Gel · 2024-12-17 · $33
Apellis PharmaceuticalsSyfovre$29
1 payment
  • Meals for Syfovre · 2024-03-29 · $29
Regeneron PharmaceuticalsEylea Hd$24
1 payment
  • Meals for Eylea Hd · 2024-12-19 · $24
Alimera SciencesYutiq$23
1 payment
  • Meals for Yutiq · 2024-02-20 · $23

2023: $1,010

Payments by company in 2023
Genentech USAVabysmo$278
5 payments
  • Meals · 2023-11-25 · $149
  • Meals for Vabysmo · 2023-10-04 · $35
  • Meals for Vabysmo · 2023-09-19 · $33
  • Meals for Vabysmo · 2023-07-26 · $34
  • Meals for Vabysmo · 2023-03-17 · $27
Regeneron Healthcare SolutionsEylea Hd$194
7 payments
  • Meals for Eylea Hd · 2023-12-06 · $32
  • Meals for Eylea Hd · 2023-12-06 · $5
  • Meals for Eylea Hd · 2023-12-05 · $38
  • Meals for Eylea Hd · 2023-10-25 · $36
  • Meals for Eylea Hd · 2023-09-26 · $21
  • Meals for Eylea · 2023-07-13 · $29
  • Meals for Eylea · 2023-04-21 · $33
Apellis PharmaceuticalsSyfovre$158
3 payments
  • Meals · 2023-11-05 · $99
  • Meals for Syfovre · 2023-09-07 · $32
  • Meals for Syfovre · 2023-03-01 · $27
AcclarentAcclarent Navwire$145
1 payment
  • Meals for Acclarent Navwire · 2023-09-29 · $145
Alcon VisionConstellation$113
1 payment
  • Meals for Constellation · 2023-11-04 · $113
Alimera SciencesIluvien$45
2 payments
  • Meals for Iluvien · 2023-11-28 · $24
  • Meals for Iluvien · 2023-01-18 · $21
AbbvieOzurdex$30
1 payment
  • Meals for Ozurdex · 2023-06-14 · $30
Regeneron PharmaceuticalsEylea$26
1 payment
  • Meals for Eylea · 2023-05-30 · $26
Bausch & Lomb AmericasXipere$22
1 payment
  • Meals for Xipere · 2023-02-13 · $22

2022: $367

Payments by company in 2022
EyePoint Pharmaceuticals USDexycu$161
2 payments
  • Meals for Yutiq · 2022-08-03 · $25
  • Meals for Dexycu · 2022-02-09 · $137
Regeneron Healthcare SolutionsEylea$87
3 payments
  • Meals for Eylea · 2022-12-14 · $23
  • Meals for Eylea · 2022-03-02 · $38
  • Meals for Eylea · 2022-02-02 · $26
Genentech USAVabysmo$77
3 payments
  • Meals for Vabysmo · 2022-11-08 · $25
  • Meals for Vabysmo · 2022-09-28 · $25
  • Meals for Susvimo · 2022-05-09 · $27
Regeneron PharmaceuticalsEylea$23
1 payment
  • Meals for Eylea · 2022-08-25 · $23
Alimera SciencesIluvien$18
1 payment
  • Meals for Iluvien · 2022-06-01 · $18

2021: $395

Payments by company in 2021
Genentech USALucentis$280
3 payments
  • Meals for Lucentis · 2021-08-19 · $124
  • Meals for Lucentis · 2021-07-22 · $136
  • Meals for Lucentis · 2021-05-05 · $20
Regeneron Healthcare SolutionsEylea$59
2 payments
  • Meals for Eylea · 2021-06-16 · $23
  • Meals for Eylea · 2021-02-02 · $36
EyePoint Pharmaceuticals USYutiq$22
1 payment
  • Meals for Yutiq · 2021-06-02 · $22
OptosPanoramic Ophthalmoscope$21
1 payment
  • Meals for Panoramic Ophthalmoscope · 2021-01-11 · $21
Alimera SciencesIluvien$13
1 payment
  • Meals for Iluvien · 2021-08-31 · $13

2020: $40

Payments by company in 2020
Genentech USALucentis$22
1 payment
  • Meals for Lucentis · 2020-02-11 · $22
Regeneron Healthcare SolutionsEylea$18
1 payment
  • Meals for Eylea · 2020-06-24 · $18

2019: $1,091

Payments by company in 2019
AllerganNone$417
1 payment
  • Education · 2019-07-14 · $417
Alcon VisionConstellation$198
2 payments
  • Meals for Constellation · 2019-10-13 · $137
  • Meals for Constellation · 2019-08-25 · $61
GenentechLucentis$150
1 payment
  • Meals for Lucentis · 2019-02-19 · $150
Genentech USALucentis$144
2 payments
  • Meals for Lucentis · 2019-10-08 · $22
  • Meals for Lucentis · 2019-03-12 · $123
Hoffmann-La RocheNon-Covered Product$107
1 payment
  • Meals for Non-Covered Product · 2019-03-21 · $107
Regeneron Healthcare SolutionsEylea$53
2 payments
  • Meals for Eylea · 2019-10-30 · $22
  • Meals for Eylea · 2019-07-02 · $30
Alimera SciencesIluvien$22
1 payment
  • Meals for Iluvien · 2019-05-14 · $22

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Aflibercept 8mg in Rvo · 2024Their institution$184,999
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 Mg in Macular Edema Secondary To Retinal Vein Occlusion · 2025Their institution$94,947
Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2021Their institution$49,333
Genentech, Inc. · A Phase 1 Sad MD in Diabetic Macular Edema · 2025Their institution$43,829
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2024Their institution$19,963
Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2019Their institution$16,787
Bayer HealthCare Pharmaceuticals Inc. · Bay865321, Hd 8mg, Amd - Ph 3 · 2022Their institution$13,973
Bayer HealthCare Pharmaceuticals Inc. · Bay865321 Hd 8mg Amd - Ph 3 · 2021Their institution$13,857
Bayer Healthcare Pharmaceuticals Inc. · Bay865321, Hd 8mg, Amd - Ph 3 · 2023Their institution$12,280
Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2022Their institution$11,135
Regeneron Pharmaceuticals, Inc. · A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe To Severe Nonproliferative Diabetic Retinopathy · 2020Their institution$5,759
Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 Mg Aflibercept in Participants With Macular Edema Following Retinal Vein Occlusion · 2025Their institution$5,000
Regeneron Pharmaceuticals, Inc. · Real-World Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Neovascular Age-Related Macular Degeneration (Namd) and Diabetic Macular Edema (Dme) Treated With Aflibercept 8 Mg in the United States · 2025Their institution$5,000
Regeneron Pharmaceuticals, Inc. · A Phase 3b Single-Arm Study of Aflibercept 8 Mg in Participants With Neovascular Age-Related Macular Degeneration (Namd) Or Diabetic Macular Edema (Dme) · 2025Their institution$5,000
Regeneron Pharmaceuticals, Inc. · A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2019This clinician$2,287
Bayer Healthcare Pharmaceuticals Inc. · Aflibercept 8mg in Rvo · 2023Their institution$92

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
100.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1053306381
Licence
CA G26383California G26383: Current · expires 2027-01-31
Trained
Stanford University School of Medicine, 1992
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00G782191
Taxonomy
Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
Mailing address
2485 Hospital Dr, Orchard Pavilion Ste 200, Mountain View, CA, 94040
NPI first listed
2005-09-13
NPI last updated
2017-12-14

This is when the NPI record was last certified, not a medical board exam.